Hence, pharmacological inhibition of Hsp90 is a propitious possibility to improve the clinical outcomes of patients with PAH, and drugs targeting Hsp90 in mitochondria may further show advantages in PAH treatment [120]. Here, HSP90AB1 is linked to pulmonary arterial hypertension.